PLX5622 is a highly selective brain-penetrant CSF1R inhibitor allowing for extended and specific microglial elimination, preceding and during pathology development.

cFMS Receptor Inhibitor II is a cFMS inhibitor.

BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM and > 3200-fold higher than its affinity for other kinases.

Ki-20227 is a highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50 value of 2 nM, displaying 6 fold and > 100 fold selectivity over VEGFR2 (IC50=12 nM) and c-Kit/PDGFRβ (IC50=451/217 nM), respectively.

Pazopanib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

GW2580 is a selective CSF-1R inhibitor for c-FMS with IC50 of 30 nM, 150- to 500-fold selective compared to b-Raf, CDK4, c-KIT, c-SRC, EGFR, ERBB2/4, ERK2, FLT-3, GSK3, ITK, JAK2 etc.

Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with IC50s of 20, 10, and 160 nM in vitro, respectively.

JNJ-40346527 is an orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R) with potential antineoplastic activity.

Linifanib is a potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively.

PRN1371 is an irreversible covalent FGFR inhibitor used for the treatment of solid tumor.